TY - JOUR
T1 - Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells
AU - Liu, Pengbo
AU - Ramachandran, Sumathi
AU - Seyed, Mohamed Ali
AU - Scharer, Christopher D.
AU - Laycock, Noelani
AU - Dalton, W. Brian
AU - Williams, Holly
AU - Karanam, Suresh
AU - Datta, Milton W.
AU - Jaye, David L.
AU - Moreno, Carlos S.
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2006/4/15
Y1 - 2006/4/15
N2 - Prostate cancer is the most commonly diagnosed noncutaneous neoplasm and second most common cause of cancer-related mortality in western men. To investigate the mechanisms of prostate cancer development and progression, we did expression profiling of human prostate cancer and benign tissues. We show that the SOX4 is overexpressed in prostate tumor samples compared with benign tissues by microarray analysis, real-time PCR, and immunohistochemistry. We also show that SOX4 expression is highly correlated with Gleason score at the mRNA and protein level using tissue microarrays. Genes affected by SOX4 expression were also identified, including BCL10, CSF1, and NcoA4/ARA70. TLE-1 and BBC3/PUMA were identified as direct targets of SOX4. Silencing of SOX4 by small interfering RNA transfection induced apoptosis of prostate cancer cells, suggesting that SOX4 could be a therapeutic target for prostate cancer. Stable transfection of SOX4 into nontransformed prostate cells enabled colony formation in soft agar, suggesting that, in the proper cellular context, SOX4 can be a transforming oncogene.
AB - Prostate cancer is the most commonly diagnosed noncutaneous neoplasm and second most common cause of cancer-related mortality in western men. To investigate the mechanisms of prostate cancer development and progression, we did expression profiling of human prostate cancer and benign tissues. We show that the SOX4 is overexpressed in prostate tumor samples compared with benign tissues by microarray analysis, real-time PCR, and immunohistochemistry. We also show that SOX4 expression is highly correlated with Gleason score at the mRNA and protein level using tissue microarrays. Genes affected by SOX4 expression were also identified, including BCL10, CSF1, and NcoA4/ARA70. TLE-1 and BBC3/PUMA were identified as direct targets of SOX4. Silencing of SOX4 by small interfering RNA transfection induced apoptosis of prostate cancer cells, suggesting that SOX4 could be a therapeutic target for prostate cancer. Stable transfection of SOX4 into nontransformed prostate cells enabled colony formation in soft agar, suggesting that, in the proper cellular context, SOX4 can be a transforming oncogene.
UR - http://www.scopus.com/inward/record.url?scp=33646256321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646256321&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-3055
DO - 10.1158/0008-5472.CAN-05-3055
M3 - Article
C2 - 16618720
AN - SCOPUS:33646256321
VL - 66
SP - 4011
EP - 4019
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 8
ER -